The Botulinum Toxins in the Treatment of Cervical Dystonia

ABSTRACT

The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of toxins, botulinum toxin type A (BTX-A) and botulinum toxin type B (BTX-B), have each been studied in large multicenter trials in subjects with CD. A study of BTX-A demonstrated improvement of 5.15 to 10.65 degrees in head position using the Cervical Dystonia Severity Scale (CDSS) in those treated with BTX-A (trade name BOTOX^℗) compared with placebo. A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc^℗) compared with placebo. The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD.

KEYWORD

Botulinum toxins - clinical trials - cervical dystonia

REFERENCES

• 1 Scott A B. Botulinum toxin injection of eye muscles to correct strabismus.  Trans Am Opthalmol Soc . 1981;  79 734-770
• 2 Green P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.  Mov Disord . 1994;  9 213-217
• 3 Mezaki T, Kaji R, Hamano T. Optimization of botulinum treatment for cervical and axial dystonias: experience with Japanese type A toxin.  J Neurol Neurosurg Psychiatry . 1994;  57 1535-1537
• 4 American BotB Cervical Dystonia Study Group. American BotB (botulinum toxin type B) in the treatment of cervical dystonia-Protocol AN072-008: an interim analysis [abstract].  Mov Disord . 1995;  10 372
• 5 Lew M F, Adornato B T, Duane D D. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.  Neurology . 1997;  49 701-707
• 6 Schiavo G, Benefenati F, Poulain B. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.  Nature . 1992;  359 832-835
• 7 DasGupta B R, Sugiyama H. Molecular form of neurotoxins in proteolytic Clostridium botulinum type B cultures.  Infect Immunol . 1976;  14 680-686
• 8 Greene P E, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.  Mov Disord . 1993;  8 479-483
• 9 Houser M K, Sheean G L, Lees A J. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.  J Neurol Neurosurg Psychiatry . 1998;  64 577-580
• 10 Ludlow C L, Hallett M, Rhew K. Therapeutic use of type F botulinum toxin.  N Engl J Med . 1992;  362 349-350
• 11 Greene P, Fahn S. Treatment of torticollis with injections of botulinum toxin type F in patients with antibodies to botulinum toxin type A [abstract].  Mov Disord . 1992;  7 134
• 12 Burgen A SV, Dickens F, Zatman L J. The action of botulinum toxin on the neuromuscular junction.  J Physiol (Lond) . 1994;  109 10-24
• 13 DasGupta B R. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin New York: Marcel Dekker 1994: 15-39
• 14 Simpson L L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.  J Pharmacol Exp Ther . 1980;  212 16-21
• 15 Brin M F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.  Mov Disord . 1997;  6 S146-S168
• 16 Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders.  Neurology . 1990;  40 1332-1336
• 17 Jankovic J, Brin M. Botulinum toxin: historical perspective and potential new indications.  Mov Disord . 1997;  6 129-144
• 18 Dendorfer M, Worle B, Breit S. Three-year follow-up on effectiveness and safety of botulinum toxin (BT) in severe axillary hyperhidrosis. WE MOVE International Conference 1999; Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Abstract 2412
• 19 Schnider P, Moraru E, Voller B. Long-term follow-up after botulinum toxin treatment for palmar and axillary hyperhidrosis. WE MOVE International Conference 1999; Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Abstract 3033
• 20 Mathew N T, Saper J R, Silberstein S D, and the BOTOX℗ Migraine Study Group. A multi-center, double-blind, placebo-controlled trial of two dosages of botulinum toxin type A (BOTOX^℗) in the prophylactic treatment of migraines.  Neurology . 1999;  52 A256
• 21 Fahn S. Concept and classification of dystonia. In: Fahn S, Marsden CD, Calne DB, eds. Dystonia 2 New York: Raven Press 1988: 1-8
• 22 Elston J S. Botulinum toxin for blepharospasm. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin: American BotB Cervical Dystonia Study Group New York: Marcel Dekker 1994: 191-197
• 23 Fahn S, List T, Moskowitz C B. Double-blind controlled study of botulinum toxin for blepharospasm [abstract].  Neurology . 1985;  35 271
• 24 Blitzer A, Brin M, Greene P E, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia.  Ann Otol Rhinol Laryngol . 1989;  98 93-97
• 25 Blitzer A, Brin M. Laryngeal dystonia: a series with botulinum toxin therapy.  Ann Otol Rhinol Laryngol . 1991;  100 85-89
• 26 Cohen L G, Hallett M, Geller B D, Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections.  J Neurol Neurosurg Psychiatry . 1989;  52 355-363
• 27 Blackie J D, Lees A J. Botulinum toxin treatment in spasmodic torticollis.  J Neurol Neurosurg Psychiatry . 1990;  53 640-643
• 28 Jankovic J, Orman J. Botulinum A toxin for cranial cervical dystonia: a double-blind, placebo-controlled study.  Neurology . 1987;  37 616-623
• 29 Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia.  Neurology . 1990;  40 277-280
• 30 Lorentz I T, Subramniam S S, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients.  Mov Disord . 1991;  6 145-150
• 31 Poewe W, Schelosky L, Kleedorfer B. Treatment of spasmodic torticollis with local injections of botulinum toxin: one year follow-up in 37 patients.  J Neurol . 1992;  239 21-25
• 32 Jahanshahi M, Marion M H, Marsden C D. Natural history of adult-onset idiopathic torticollis.  Arch Neurol . 1990;  47 548-552
• 33 Tsui J, Eisen A, Stoessel A J. Double-blind study of botulinum toxin and spasmodic torticollis.  Lancet . 1986;  2 245-246
• 34 Gelb D J, Lowenstein D H, Aminoff M J. Controlled trial of botulinum toxin injections in treatment of spasmodic torticollis.  Neurology . 1989;  39 80-84
• 35 Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis.  Eur Neurol . 1993;  33 199-203
• 36 Moore A P, Blumhardt L D. A double-blind trial of botulinum toxin ``A'' in torticollis with one year follow up.  J Neurol Neurosurg Psychiatry . 1991;  54 813-816
• 37 Green P, Kang U, Fahn S. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis.  Neurology . 1990;  40 1213-1218
• 38 Comella C L, Bachman A S, Tanner C M, Brown-Toms N C, Goetz C G. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.  Neurology . 1992;  42 878-882
• 39 Brashear A, Truong B, Charles D. A randomized, double-blind, placebo-controlled study of intramuscular BOTOX^℗ for the treatment of cervical dystonia [abstract].  Mov Disord . 1998;  13 276
• 40 Brashear A, Cullis P, Moiho E. Cervical Dystonia Severity Scale (CDSS) reliability study [abstract].  Mov Disord . 1998;  13 275
• 41 Brashear A, Lew M R, Dykstra D D. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.  Neurology . 1999;  53 1439-1446
• 42 Brin M F, Lew M F, Adler C H. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.  Neurology . 1999;  53 1438-1441
• 43 Hambleton P, Moore A P. Botulinum neurotoxins: origin, structure, molecular actions, and antibodies. In: Moore P, ed. Handbook of Botulinum Toxin Treatment London: Blackwell Science 1995: 16-27
• 44 Sakaguchi G. Clostridium botulinum toxins.  Pharmacol Ther . 1983;  19 165-194
• 45 Siegel L S. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.  J Clin Microbiol . 1989;  27 1906-1908
• 46 Schiavo G, Santucci A, DasGupta B R. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH terminal peptide bonds.  FEBS Lett . 1993;  335 99-103
• 47 Schiavo G, Rosetto O, Santucci A. Identification of the nerve terminal targets of botulinum neurotoxin serotype A, serotype D, and serotype E.  J Biol Chem . 1993;  268 23784-23787
• 48 Jankovic J. Treatment of dystonia. In: Watts RL, Koller WC, eds. Movement Disorders: Neurological Principles and Practice New York: McGraw-Hill 1997: 443-454
• 49 Consky E S, Basinski A, Belle L. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability [abstract].  Neurology . 1994;  40 445
• 50 Consky E S, Lang A E. Assessment of cervical dystonia: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). In: Jankovic J, Hallet M, eds. Therapy with Botulinum Toxin: Neurological Disease and Therapy Series Vol. 25. Koller WC, series ed. New York: Marcel Dekker 1994: 224-226
• 51 Kaplan E L, Meier P. Nonparametric estimation from incomplete observations.  J Am Stat Assoc . 1958;  53 457-481